Psychedelic Therapy Scrutinized by FDA Advisory Committee?
JAMA July 30, 2024 DOI: 10.1001/jama.2024.13370 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint or commentary Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Advisory committee Family medicine Management |
| Citations | 20 |
| Key points | Argues that the advisory committee's decisions on MDMA-assisted therapy carry significant implications for the trajectory of psychedelic research. |
Abstract
This Viewpoint analyzes the Psychopharmacologic Drugs Advisory Committee’s decisions regarding 3,4-methylenedioxymethamphetamine–assisted therapy and what they mean for psychedelic research.
Citations in the library
Cited by 20
- Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism. The American Journal of Bioethics 2025
- An international Delphi consensus for reporting of setting in psychedelic clinical trials. Nature Medicine June 3, 2025
- Addressing blinding in classic psychedelic studies with innovative active placebos. The International Journal of Neuropsychopharmacology April 1, 2025
- Psychedelic Medicine Exceptionalism. The American Journal of Bioethics 2025
- A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy. Journal of Psychopharmacology April 1, 2025
and 15 more in the library
Cites 3
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine October 1, 2023
- How Should the FDA Evaluate Psychedelic Medicine? New England Journal of Medicine November 4, 2023